Is There Any Risk for Metabolic Syndrome in Children and Adolescents with Psychiatric Disorders?

Basit Öğe Kaydı
dc.authoridTahillioglu, Akin/0000-0002-3952-3672
dc.authoridÖnder, arif/0000-0003-0571-9295
dc.authorwosidTahillioglu, Akin/HLG-4928-2023
dc.authorwosidÖnder, arif/ABC-7365-2021
dc.contributor.authorBilac, Oznur
dc.contributor.authorTahillioglu, Akin
dc.contributor.authorCakir, Burak
dc.contributor.authorKavurma, Canem
dc.contributor.authorOnder, Arif
dc.contributor.authorErcan, Eyup Sabri
dc.date.accessioned2024-03-09T18:48:36Z
dc.date.available2024-03-09T18:48:36Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractObjective: We aimed to investigate the risk of antipsychotic drug treatment in the development of metabolic syndrome (MetS) in children and adolescents and to determine which psychiatric disorder is more associated with MetS in the pediatric population. Methods: The sample consisted of 118 children and adolescents (88 used psychotropic medication). The hemogram, fasting blood glucose, lipid profile, weight, and blood pressure levels of all the participants and information regarding medication doses of the patient group at the sixth month of the treatment process were obtained. Results: Bipolar disorder (BPD) was the only psychiatric disorder associated with MetS. Quetiapine and valproic acid were found to have increasing effects on MetS. Weight gain and the increase in systolic and diastolic blood pressure significantly increased the likelihood of MetS. Hierarchical logistic regression analyses revealed that quetiapine increased the risk of MetS through weight gain, and valproic acid increased MetS risk through systolic blood pressure. Conclusion: Especially BPD and psychotropic use in children and adolescents disrupt metabolic regulation and pose a risk for MetS. Determining the risk factors causing MetS, especially in children and adolescents, plays a significant role in preventing mortality and morbidity at advanced ages.en_US
dc.identifier.doi10.1159/000533470
dc.identifier.endpage273en_US
dc.identifier.issn2571-726X
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85179857335en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage261en_US
dc.identifier.urihttps://doi.org/10.1159/000533470
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1407
dc.identifier.volume6en_US
dc.identifier.wosWOS:001069791400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofDubai Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetabolic Syndrome; Weight Gain; Blood Pressure; Antipsychotics; Psychiatric Disorder; Bipolar Disorder; Children And Adolescents; Quetiapine; Valproic Aciden_US
dc.titleIs There Any Risk for Metabolic Syndrome in Children and Adolescents with Psychiatric Disorders?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1407.pdf
Boyut:
531.59 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu